Roche Maintains Stability – CEO Thomas Schinecker Assures Workforce Levels Will Not Drop

Swiss pharmaceutical giant Roche remains on solid footing with no immediate plans for job reductions, according to recent statements by CEO Thomas Schinecker in a Swiss newspaper interview.

While the company’s share value has significantly dropped from its peak in April 2022, concerns about potential layoffs amid recent challenges in drug development—especially in oncology—were addressed by Schinecker. He assured that workforce levels are either stable or marginally increasing.

Schinecker emphasized the robustness of Roche’s operations, pointing to a steady research and development budget as a key indicator of the company’s health. He dismissed concerns about growth, reiterating that Roche is not facing any substantial business hurdles.

On the much-anticipated anti-obesity drug, Schinecker projected its market debut by 2029, possibly earlier.

Discussing broader economic trends, Schinecker acknowledged ongoing challenges in Europe and China, contrasting them with modest growth in the United States. He noted that Europe’s recovery would likely require more time, given the persistent economic headwinds.

The CEO’s remarks underline Roche’s commitment to navigating current challenges while maintaining a strong operational foundation.

Have you read?
Best CEOs.
Best Companies.
Richest People (Billionaire).
Richest Women (Billionaire).
Richest in Each Country (Billionaire).